---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-025491"
form_type: "8-K"
ticker: "DARE"
cik: "0001401914"
company_name: "Dare Bioscience, Inc."
filed_at: "2025-12-01T23:59:59+00:00"
generated_at: "2026-05-16T15:52:06.976551+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Bayer terminates Ovaprene license; Daré regains full rights, Phase 3 study continues

## Summary
- Bayer HealthCare terminated Ovaprene license agreement effective Feb 24, 2026 due to strategic prioritization.
- Daré regains full commercialization rights to Ovaprene, a hormone-free monthly intravaginal contraceptive.
- Pivotal Phase 3 study continues with positive interim data (July 2025) and Gates Foundation grant support.
- Enrollment expected to complete in 2026; no change to timelines or operations.
- Daré to explore partnerships and strategic transactions for Ovaprene.

## SEC filing metadata
- accession: 0001493152-25-025491
- form_type: 8-K
- ticker: DARE
- cik: 0001401914
- company_name: Dare Bioscience, Inc.
- filed_at: 2025-12-01T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1401914/000149315225025491/0001493152-25-025491-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1401914/000149315225025491/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-025491
- JSON: https://secwatch.observer/filing/0001493152-25-025491.json
- Plain text: https://secwatch.observer/filing/0001493152-25-025491.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.